Skip to Content
Merck
All Photos(1)

Key Documents

36-008

Sigma-Aldrich

Anti-α-Synuclein Antibody, clone Syn211

ascites fluid, clone Syn211, Upstate®

Synonym(s):

Anti-NACP, Anti-PARK1, Anti-PARK4, Anti-PD1

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

ascites fluid

antibody product type

primary antibodies

clone

Syn211, monoclonal

species reactivity

human

packaging

antibody small pack of 25 μL

manufacturer/tradename

Upstate®

technique(s)

immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

NCBI accession no.

UniProt accession no.

shipped in

ambient

target post-translational modification

unmodified

Gene Information

human ... SNCA(6622)

Specificity

α-Synuclein

Immunogen

full-length recombinant human α-Synuclein

Application

Detect α-Synuclein using this Anti-α-Synuclein Antibody, clone Syn211 validated for use in IP, WB, IH.
Research Category
Neuroscience
Research Sub Category
Neurodegenerative Diseases

Quality

Routinely evaluated by immunoblot on Alzheimer′s diseased human whole brain lysates.

Target description

~14.5kDa

Linkage

Replaces: 04-1053

Physical form

Ascites

Storage and Stability

2 years at -20°C

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jay S Schneider et al.
Molecular and cellular neurosciences, 120, 103729-103729 (2022-04-22)
Among the pathological events associated with the dopaminergic neurodegeneration characteristic of Parkinson's disease (PD) are the accumulation of toxic forms of α-synuclein and microglial activation associated with neuroinflammation. Although numerous other processes may participate in the pathogenesis of PD, the
Sarah M O'Donovan et al.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, 32(1), e13726-e13726 (2019-10-03)
A hallmark feature of Parkinson's disease (PD) is the build-up of α-synuclein protein aggregates throughout the brain; however α-synuclein is also expressed in enteric neurons. Gastrointestinal (GI) symptoms and pathology are frequently reported in PD, including constipation, increased intestinal permeability
Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors.
Hall, H; Jewett, M; Landeck, N; Nilsson, N; Schagerlof, U; Leanza, G; Kirik, D
Testing null
Sandra Cuellar-Baena et al.
Journal of neurochemistry, 137(5), 806-819 (2016-01-27)
In this study, we used proton-localized spectroscopy ((1) H-MRS) for the acquisition of the neurochemical profile longitudinally in a novel rat model of human wild-type alpha-synuclein (α-syn) over-expression. Our goal was to find out if the increased α-syn load in
Rachel Kelly et al.
Molecules (Basel, Switzerland), 27(2) (2022-01-22)
Since the discovery of α-synuclein as the major component in Lewy bodies, research into this protein in the context of Parkinson's disease pathology has been exponential. Cannabinoids are being investigated as potential therapies for Parkinson's disease from numerous aspects, but

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service